Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine

References

• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Muller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38. doi:10.1007/s40121-018-0213-2.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Brynildsrud OB. Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nat Rev Microbiol. 2020;18(2):84–96. doi:10.1038/s41579-019-0282-6.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2):S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019 [accessed 2019 Oct 16]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf.
   Google Scholar
• Christensen H, Al-Janabi H, Levy P, Postma MJ, Bloom DE, Landa P, Damm O, Salisbury DM, Diez-Domingo J, Towse AK, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21(2):297–309. doi:10.1007/s10198-019-01129-z.
   PubMed Web of Science ®Google Scholar
• Stawasz A, Huang L, Kirby P, Bloom D. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination’s full social and economic benefits. Front Public Health. 2020;8:261. doi:10.3389/fpubh.2020.00261.
   PubMed Web of Science ®Google Scholar
• Knol MJ, Ruijs WL, Antonise-Kamp L, De Melker HE, Van Der Ende A. Implementation of menACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill. 2018;23(16):18–00158. doi:10.2807/1560-7917.ES.2018.23.16.18-00158.
   PubMedGoogle Scholar
• Public Health England. Meningococcal ACWY immunisation programme for adolescents information for healthcare professionals. London (UK): Crown; 2020 [accessed 2020 Oct 16]. https://www.gov.uk/government/publications/menacwy-programme-information-for-healthcare-professionals.
   Google Scholar
• Clark SA, Lucidarme J, Angel G, Lekshmi A, Morales-Aza B, Willerton L, Campbell H, Gray SJ, Ladhani SN, Wade M, et al. Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England. Sci Rep. 2019;9(1):9990. doi:10.1038/s41598-019-46483-3.
   PubMedGoogle Scholar
• Grogan J, Roos K. Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination. Curr Infect Dis Rep. 2017;19(9):30. doi:10.1007/s11908-017-0587-4.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49(1):e1–10. doi:10.1086/599117.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30(3):e41–48. doi:10.1097/INF.0b013e3182054ab9.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24. doi:10.1016/s0140-6736(11)61713-3.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349–62. doi:10.1056/NEJMoa1614474.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Vaccine schedules in all countries of the European Union. [accessed 2019 Oct 15]. https://vaccine-schedule.ecdc.europa.eu/.
   Google Scholar
• Norwegian Institute of Public Health. Norwegian surveillance system for communicable diseases. Oslo (Norway): Norwegian Institute of Public Health; [accessed 2019 Dec 16]. http://msis.no/.
   Google Scholar
• Taylor K. Norwegian teens celebrate a bizarre, month-long holiday full of drinking, sex, and wild dares — here’s what it’s like. Business Insider. 2018 Apr 18 [cited 2019 Dec 16]. https://www.businessinsider.com/what-the-norwegian-teen-holiday-russefeiring-is-like-2017-6?r=US&IR=T.
   Google Scholar
• Norwegian Immunisation Registry SYSVAK. Oslo (Norway): Norwegian Institute of Public Health; 2019 [accessed 2019 Apr 10]. https://www.fhi.no/en/hn/health-registries/norwegian-immunisation-registry-sysvak/.
   Google Scholar
• Alarid-Escudero F, Krijkamp EM, Enns EA, Myriam Hunink MG, Pechlivanoglou P, Jalal H. Cohort state-transition models in R: a tutorial. arXiv:200107824. 2020 Jan 22 [cited 2020 Feb 24]. https://ui.adsabs.harvard.edu/abs/2020arXiv200107824A.
   Google Scholar
• Krijkamp EM, Alarid-Escudero F, Enns EA, Pechlivanoglou P, Hunink MGM, Yang A, Jalal HJ. A multidimensional array representation of state-transition model dynamics. Medical Decision Making. 2020;40(2):242–48. doi:10.1177/0272989x19893973.
   PubMed Web of Science ®Google Scholar
• Norwegian Ministry of Finance. Oslo (Norway); [accessed 2019 Oct 9]. https://www.regjeringen.no/en/dep/fin/id216/
   Google Scholar
• Norwegian Medicines Agency. Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals. Oslo (Norway): Norwegian Medicines Agency; 2018 [accessed 2019 Oct 10]. https://legemiddelverket.no/Documents/English/Public%20funding%20and%20pricing/Documentation%20for%20STA/Guidelines_april_2018.pdf.
   Google Scholar
• Norheim O, Allgott B, Gjul G, Kjellevold A, Moen A, Sjøli S, Aschim B, Gundersen T, Kvinnsland S, Ø M, et al. Norwegian [Transparent and fair – priorities in health services]. Oslo (Norway): Norwegian Government; 2014. https://www.regjeringen.no/no/dokumenter/NOU-2014-12/id2076730/?ch=1.
   Google Scholar
• Statistics Norway. Oslo (Norway); [accessed 2019 Oct 9]. https://www.ssb.no/en/.
   Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013;32(4):e170–177. doi:10.1097/INF.0b013e318279ac38.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van Der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236–43. doi:10.1097/inf.0000000000000866.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–31. doi:10.1016/s0140-6736(14)60842-4.
   PubMed Web of Science ®Google Scholar
• Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–30. doi:10.1080/21645515.2018.1454570.
   PubMed Web of Science ®Google Scholar
• Norwegian: [Statistics for childhood vaccination]. Oslo (Norway): Norwegian Institute of Public Health; 2018 [accessed 2019 Oct 14]. https://www.fhi.no/hn/helseregistre-og-registre/sysvak/barnevaksinasjon—statistikk/.
   Google Scholar
• EQ-5D (EuroQo 5 dimensions). Rotterdam (The Netherlands): EuroQol Group; 2020 [accessed 2019 Oct 9]. https://euroqol.org/.
   Google Scholar
• Sun S, Irestig R, Burstrom B, Beijer U, Burstrom K. Health-related quality of life (EQ-5D) among homeless persons compared to a general population sample in Stockholm county, 2006. Scand J Public Health. 2012;40(2):115–25. doi:10.1177/1403494811435493.
   PubMed Web of Science ®Google Scholar
• Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–35. doi:10.1023/a:1013171831202.
   PubMed Web of Science ®Google Scholar
• Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21–25. doi:10.1016/j.jpeds.2009.01.040.
   PubMed Web of Science ®Google Scholar
• Stoof SP, Rodenburg GD, Knol MJ, Rumke LW, Bovenkerk S, Berbers GA, Spanjaard L, Van Der Ende A, Sanders EA. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281–92. doi:10.1093/cid/civ506.
   PubMed Web of Science ®Google Scholar
• Exchange rates. Oslo (Norway): Norges Bank; 2018 [accessed 2019 Oct]. https://www.norges-bank.no/en/topics/Statistics/exchange_rates/.
   Google Scholar
• Norwegian Medicines Agency. Oslo (Norway); [accessed 2019 Oct 14]. https://legemiddelverket.no/english.
   Google Scholar
• Norwegian: [ISF_regulations_2018 – DRGlist somatic]. Norwegian Directorate of Health; 2018 [accessed 2019 Oct 14]. https://www.helsedirektoratet.no/tema/finansiering/innsatsstyrt-finansiering-og-drg-systemet/innsatsstyrt-finansiering-isf/ISF_Regelverk_2018%20%E2%80%93%20DRGliste%20Somatikk%20(Vedlegg%20A1).xlsx?download=true.
   Google Scholar
• De Wals P, Zhou Z. Cost-effectiveness comparison of monovalent C versus quadrivalent ACWY meningococcal conjugate vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):e203–e207. doi:10.1097/inf.0000000000001512.
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics – Nimenrix. European Medicines Agency; [accessed 2019 Oct 28]. https://www.ema.europa.eu/en/documents/product-information/nimenrix-epar-product-information_en.pdf.
   Google Scholar
• Summary of Product Characteristics – Menveo. European Medicines Agency; [accessed 2019 Oct 28]. https://www.ema.europa.eu/en/documents/product-information/menveo-epar-product-information_en.pdf.
   Google Scholar
• Norwegian Ministry of Health and Care Services. Principles for priority setting in health care - Summary of a white paper on priority setting in the norwegian health care sector. Oslo (Norway): Norwegian Government; 2016. https://www.regjeringen.no/contentassets/439a420e01914a18b21f351143ccc6af/en-gb/pdfs/stm201520160034000engpdfs.pdf.
   Google Scholar
• Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–35. doi:10.1016/j.jval.2016.02.017.
   PubMed Web of Science ®Google Scholar
• Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Making. 2014;34(3):311–26. doi:10.1177/0272989x13505910.
   PubMed Web of Science ®Google Scholar
• Watle SV, Caugant DA, Tunheim G, Bekkevold T, Laake I, Brynildsrud OB, Næss LM. Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors. Epidemiol Infect. 2020;148:e80. doi:10.1017/s0950268820000734.
   PubMed Web of Science ®Google Scholar
• Hepkema H, Pouwels KB, Van Der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLoS One. 2013;8(5):e65036. doi:10.1371/journal.pone.0065036.
   PubMed Web of Science ®Google Scholar
• Si S, Zomer E, Fletcher S, Lee J, Liew D. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019;37(35):5009–15. doi:10.1016/j.vaccine.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1–13. doi:10.1086/524041.
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–32. doi:10.1542/peds.2004-2514.
   PubMed Web of Science ®Google Scholar
• Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS One. 2017;12(5):e0175721. doi:10.1371/journal.pone.0175721.
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine. 2007;25(29):5433–40. doi:10.1016/j.vaccine.2007.04.071.
   PubMed Web of Science ®Google Scholar
• Vetter V, Baxter R, Denizer G, Safadi MA, Silfverdal SA, Vyse A, Borrow R. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641–58. doi:10.1586/14760584.2016.1130628.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Jorgensen HJ, Caugant DA. Serogroup A meningococcal conjugate vaccines in Africa. Expert Rev Vaccines. 2015;14(11):1441–58. doi:10.1586/14760584.2015.1084232.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851–61. doi:10.1586/erv.09.48.
   PubMed Web of Science ®Google Scholar
• Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509–22. doi:10.1007/s40273-017-0606-1.
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• Al-Janabi H, Van Exel J, Brouwer W, Trotter C, Glennie L, Hannigan L, Coast J. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529–44. doi:10.1002/hec.3259.
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, Mccabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O’hagan T. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–47. doi:10.1002/hec.985.
   PubMed Web of Science ®Google Scholar
• Im JH, Woo H, Ha BM, Lee JS, Chung MH, Jung J. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces. Vaccine. 2019;38(4):730–32. doi:10.1016/j.vaccine.2019.11.015.
   PubMed Web of Science ®Google Scholar
• Cohn AC, Macneil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193. doi:10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar